We are a privately-held, venture-backed, pre-revenue stage company located in Laguna Hills, California, developing novel radiofrequency balloon catheter technology directed towards a variety of clinical applications including (i) the treatment of medication resistant hypertension via percutaneous renal denervation and (ii) peripheral in-stent restenosis.

Our newest product, the V2 System for hypertension promises to greatly simplify the renal denervation procedure by employing a novel RF balloon catheter specifically designed for this clincial application. The Company expects to begin its REDUCE-HTN clinical study at 10 international clinical sites in Q1 2012.

The Company's initial product, the ZCath System has a European CE Mark for the indication of reducing plaque in peripheral arteries and expects to continue its clinical study for peripheral in-stent restenosis - RAPTOR at 2 clinical sites in Germany during 2012.

Vessix Vascular is ISO 13485 Compliant.

Vessix products are not cleared for sale in the United States. Claims made on this website are based on limited clinical studies.